RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 57 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 57

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  3. Study siteAffiliated Hospital of Southwest Medical University西南医科大学附属医院LuzhouHospital page
  4. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  5. Study siteAnhui Provincial Cancer HospitalCity not listedHospital page
  6. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  7. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  8. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  9. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  10. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  11. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  12. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  13. Study siteFirst Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第一医院(浙江省中医院)HangzhouHospital page
  14. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  15. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  16. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  17. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  18. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  19. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  20. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  21. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  22. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  23. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  24. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  25. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  26. Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
  27. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  28. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  29. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  30. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  31. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  32. Study siteMeizhou People's Hospital梅州市人民医院MeizhouHospital page
  33. Study siteNanchang People's HospitalNanchangHospital page
  34. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  35. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  36. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  37. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  38. Study sitePeking University Shenzhen Hospital北京大学深圳医院ShenzhenHospital page
  39. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  40. Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
  41. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  42. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  43. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  44. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  45. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  46. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  47. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  48. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  49. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  50. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  51. Study siteXijing Hospital空军军医大学西京医院Xi'anHospital page
  52. Study siteXinhua Hospital上海交通大学医学院附属新华医院ShanghaiHospital page
  53. Study siteXuzhou Central Hospital徐州市中心医院XuzhouHospital page
  54. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  55. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  56. Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page
  57. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05696626, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histological or cytological confirmation of ER+/HER2 - disease

    Inclusion criterion 3

  3. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.

    Exclusion criterion 2

    Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).

    Exclusion criterion 6

    History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).

    Exclusion criterion 9

  4. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

    Inclusion criterion 8

  5. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

    Inclusion criterion 6

    Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).

    Inclusion criterion 15

  6. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).

    Exclusion criterion 15

    History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.

    Exclusion criterion 16

  7. Positive serum pregnancy test (only if premenopausal).

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05696626, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Pre- or postmenopausal women or men.
  • Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.
  • Histological or cytological confirmation of ER+/HER2 - disease
  • No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.
  • At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.
  • Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.
  • Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
  • Adequate organ function
  • Able to swallow tablets
  • Brain metastases are allowed only if the following 4 parameters hold:
  • Asymptomatic,
  • Definitively treated (e.g., radiotherapy, surgery),
  • Not requiring steroids up to 4 weeks before study treatment initiation, AND
  • Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  • Able to understand and voluntarily sign a written informed consent before any screening procedures.
  • Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion Criteria:

  • Lymphangitic carcinomatosis involving the lung.
  • History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  • Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  • Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  • Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  • Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  • Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  • History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  • History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  • Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  • On concomitant strong CYP3A4 inhibitors.
  • On strong and moderate CYP3A4 inducers.
  • Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  • Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  • Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  • History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  • Positive serum pregnancy test (only if premenopausal).
  • Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  • Women who are breast feeding
  • History of non-compliance to medical regimens.
  • Unwilling or unable to comply with the protocol.
  • Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  • Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  • Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  • Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

Quoted from ClinicalTrials.gov, NCT05696626, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05696626, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05696626